Ion mobility spectrometry combined with multivariate statistical analysis: revealing the effects of a drug candidate for Alzheimer’s disease on Aβ1-40 peptide early assembly

Abstract

Inhibition of the initial stages of amyloid-β peptide self-assembly is a key approach in drug development for Alzheimer’s disease, in which soluble and highly neurotoxic low molecular weight oligomers are produced and aggregate in the brain over time. Here we report a high-throughput method based on ion mobility mass spectrometry and multivariate statistical analysis to rapidly select statistically significant early-stage species of amyloid-β1-40 whose formation is inhibited by a candidate theranostic agent. Using this method, we have confirmed the inhibition of a Zn-porphyrin-peptide conjugate in the early self-assembly of Aβ40 peptide. The MS/MS fragmentation patterns of the species detected in the samples containing the Zn-porphyrin-peptide conjugate suggested a porphyrin-catalyzed oxidation at Met-35(O) of Aβ40. We introduce ion mobility MS combined with multivariate statistics as a systematic approach to perform data analytics in drug discovery/amyloid research that aims at the evaluation of the inhibitory effect on the Aβ early assembly in vitro models at very low concentration levels of Aβ peptides. Electronic supplementary material The online version of this article (10.1007/s00216-019-02030-7) contains supplementary material, which is available to authorized users.

Targeted and Untargeted Mass Spectrometry Reveals the Impact of High-Fat Diet on Peripheral Amino Acid Regulation in a Mouse Model of Alzheimer’s Disease

“…For the purpose of these discovery studies, significantly changed metabolites were chosen with the criteria p -value <0.05 and |FC| > 2. Differences in metabolomics profiles between groups were assessed by principal component analysis (PCA) using log-transformed, Pareto-scaled data in MetaboAnalyst software. − Data were normalized to all compounds and protein amount-adjusted using Progenesis QI prior to being uploaded on MetaboAnalyst 4.0.…”

Refining the amyloid β peptide and oligomer fingerprint ambiguities in Alzheimer’s disease: Mass spectrometric molecular characterization in brain, cerebrospinal fluid, blood, and plasma

“…and also toxicity (Lys16) (Sinha et al, 2012); role of Gly25-Ser26 dipeptide bond in organizing Aβ42 monomer structure (Roychaudhuri et al, 2014); intra-species aggregation differences based on primary amino acid sequence (Roychaudhuri et al, 2015); and formation of distinct oligomeric species in various membrane-mimicking environments (Österlund et al, 2019). Recently, it was also used to demonstrate the effect of a drug candidate on the very early assembly of the Aβ1-40 peptide (Lazzaro et al, 2019).…”

The F19W mutation reduces the binding affinity of the transmembrane Aβ11–40 trimer to the membrane bilayer

“…The collision cross section (CCS) is an important parameter for describing proteins in both experimental and computational methods. In experiments, CCS can be estimated by ion mobility mass spectrometry (IM-MS), 81,82 while computationally, it can been calculated by the IMPACT method. 67,83 CCS values of the representative structures based on IMPACT with the trajectory method are shown in Table 1.…”